NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering ...
Strategy has launched a $2.1 billion At-The-Market (ATM) equity program for its Strife (STRF) preferred stock, marking another step in the firm’s long-term strategy to build a Bitcoin-backed financial ...
Atlanta-based global payments technology company Brightwell launched its ATM program solutions that “offer a cost-effective way for the cruise industry to drive revenue while lowering ATM operation ...
Daix (France), New York City (New York, United States), October 14, 2025 - Inventiva (Euronext Paris and Nasdaq : IVA) ("Inventiva” or the "Company”), a clinical-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback